AR127562A1 - ANTICUERPOS CONTRA EL FACTOR DE NECROSIS TUMORAL a HUMANO - Google Patents

ANTICUERPOS CONTRA EL FACTOR DE NECROSIS TUMORAL a HUMANO

Info

Publication number
AR127562A1
AR127562A1 ARP220103012A ARP220103012A AR127562A1 AR 127562 A1 AR127562 A1 AR 127562A1 AR P220103012 A ARP220103012 A AR P220103012A AR P220103012 A ARP220103012 A AR P220103012A AR 127562 A1 AR127562 A1 AR 127562A1
Authority
AR
Argentina
Prior art keywords
human
nucleic acid
antibodies against
necrosis factor
vector
Prior art date
Application number
ARP220103012A
Other languages
English (en)
Inventor
Grace Chao
Yiqing Feng
Donmienne Doen Mun Leung
Songqing Na
Bharathi Ramamurthy
Jianghuai Xu
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR127562A1 publication Critical patent/AR127562A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente descripción se refiere a anticuerpos que se unen específicamente a formas solubles y de membrana del TNFa humano, composiciones que comprenden dichos anticuerpos contra el TNFa y métodos para usar dichos anticuerpos contra el TNFa y composiciones. Reivindicación 20: Un ácido nucleico que comprende una secuencia que codifica la SEQ ID Nº 9, 10, 18, 19, 25, 28, 35 o 36. Reivindicación 21: Un vector que comprende el ácido nucleico de la reivindicación 20. Reivindicación 23: Una composición que comprende un primer vector que comprende una secuencia de ácido nucleico que codifica la SEQ ID Nº 9, 18, 25 o 35, y un segundo vector que comprende una secuencia de ácido nucleico que codifica la SEQ ID Nº 10, 19, 28 o 36. Reivindicación 25: La célula de la reivindicación 24, en donde la célula es una célula de mamífero.
ARP220103012A 2021-11-11 2022-11-02 ANTICUERPOS CONTRA EL FACTOR DE NECROSIS TUMORAL a HUMANO AR127562A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163278245P 2021-11-11 2021-11-11

Publications (1)

Publication Number Publication Date
AR127562A1 true AR127562A1 (es) 2024-02-07

Family

ID=84799771

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220103012A AR127562A1 (es) 2021-11-11 2022-11-02 ANTICUERPOS CONTRA EL FACTOR DE NECROSIS TUMORAL a HUMANO

Country Status (6)

Country Link
US (1) US20230192837A1 (es)
AR (1) AR127562A1 (es)
AU (1) AU2022386645A1 (es)
CA (1) CA3237268A1 (es)
TW (1) TW202334220A (es)
WO (1) WO2023086871A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240082414A1 (en) * 2022-05-13 2024-03-14 Eli Lilly And Company Human tumor necrosis factor alpha antibody glucocorticoid conjugates

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7073487B2 (ja) 2017-06-16 2022-05-23 イーライ リリー アンド カンパニー 操作された抗体化合物およびこれらの抱合体

Also Published As

Publication number Publication date
US20230192837A1 (en) 2023-06-22
WO2023086871A3 (en) 2023-06-22
TW202334220A (zh) 2023-09-01
CA3237268A1 (en) 2023-05-19
WO2023086871A2 (en) 2023-05-19
AU2022386645A1 (en) 2024-05-16

Similar Documents

Publication Publication Date Title
AR127562A1 (es) ANTICUERPOS CONTRA EL FACTOR DE NECROSIS TUMORAL a HUMANO
AR107444A1 (es) Composición farmacéutica que comprende constructos de anticuerpo biespecíficos
AR110093A1 (es) D-psicosa 3-epimerasa y método para preparar d-psicosa utilizando la misma
AR103162A1 (es) Anticuerpos anti-c5 y métodos para su uso
PE20181923A1 (es) Neoantigenos y metodos de su uso
CO2022011467A2 (es) Polipéptidos, composiciones y su uso para tratar o limitar el desarrollo de una infección
EA201990861A1 (ru) Рнк-направляемые модифицирующие нуклеиновые кислоты ферменты и способы их применения
AR095596A1 (es) Moléculas de unión de cadena única comprendiendo n-terminal abp
AR078795A1 (es) Inmunoglobulinas con dominio variable dual y usos de las mismas
ES2663872T3 (es) Composición inmunogénica o vacuna contra infección o enfermedad bacteriana gramnegativa, por ejemplo, por Neisseria
CL2020001821A1 (es) Formulación de adenovirus del grupo b.
AR071232A1 (es) Proteina hibrida usada como vacuna contra toxinas shiga de e. coli
BR112022008533A2 (pt) Composição para aumento da biodisponibilidade sanguínea de aminoácidos, seu uso, produto alimentício, uso de uma mistura, e usos de cepas bacterianas probióticas
AR092630A1 (es) Metodos y composiciones para prevenir la incorporacion erronea de norleucina en proteinas
AR109799A1 (es) Composición para el tratamiento del cabello
CR20170507A (es) Fusiones de variante iii del receptor de factor de crecimiento epidérmico-mesotelina y métodos para usar los mismos.
CO2023002980A2 (es) Vector de poxviridae recombinante que expresa moléculas coestimuladoras
CL2023001816A1 (es) Parapoxvirus modificado que tiene inmunogenicidad incrementada
CO2022016968A2 (es) Terapia génica con vectores duales de disferlina
MX2016010623A (es) Anticuerpo para sesgar proporciones de sexos y metodos de uso del mismo.
AR125379A1 (es) Un fab anti-tslp con estabilidad mejorada
BR112022019356A2 (pt) Moléculas bifuncionais e métodos de uso das mesmas
CO2023005403A2 (es) Vector dlx2
MX2022001209A (es) Receptores de linfocitos t y métodos de uso de estos.
MX2021010533A (es) Receptores de linfocitos t y metodos de uso de estos.